Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

102.59
+1.531.51%
Volume:182.50K
Turnover:18.53M
Market Cap:7.06B
PE:-32.91
High:102.84
Open:99.88
Low:99.88
Close:101.06
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:0.51
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:68.59
PE(LYR):-32.99

Loading ...

Rhythm Pharmaceuticals Highlights Imcivree Launch Progress in Acquired Hypothalamic Obesity Presentation

Reuters
·
Sep 09

Rhythm Pharma CFO Hunter C. Smith Disposes of Common Shares Worth $6.61 Million

Reuters
·
Sep 02

Will Japan’s First IMCIVREE Approval in Hypothalamic Obesity Change Rhythm Pharmaceuticals’ (RYTM) Narrative

Simply Wall St.
·
Aug 31

Rhythm Pharmaceuticals Initiated at Hold by Deutsche Bank

Dow Jones
·
Aug 28

Rhythm Pharmaceuticals, Inc. : Deutsche Bank Initiates Coverage with Hold Rating and Target Price $120

THOMSON REUTERS
·
Aug 28

Rhythm Pharmaceuticals initiated with a Hold at Deutsche Bank

TIPRANKS
·
Aug 28

Rhythm Pharmaceuticals (RYTM) Could Be 15% Undervalued As Japan Approval Lifts Its Story

Simply Wall St.
·
Aug 26

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Aug 25

Rhythm Pharma Says Japan Regulator Approves Imcivree for Acquired Hypothalamic Obesity

Reuters
·
Aug 24

Rhythm Pharmaceuticals, - Imcivree Launch in Japan Expected by End of 2026 Pending Pricing

THOMSON REUTERS
·
Aug 24

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity

Simply Wall St.
·
Aug 22

Rhythm Pharma Files Form 3 for Chief Medical Officer Manher Joshi

Reuters
·
Aug 19

Rhythm Pharmaceuticals Appoints Manher “AJ” Joshi as Chief Medical Officer

Reuters
·
Aug 17

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer

THOMSON REUTERS
·
Aug 17

Rhythm Pharma EVP, Head of International Yann Mazabraud Sells USD 6.61 Million in Common Shares

Reuters
·
Aug 15

UK MHRA Expands Rhythm’s Imcivree Authorization to Treat Acquired Hypothalamic Obesity

Reuters
·
Aug 11

Rhythm Pharmaceuticals: to Work Closely with UK's Nhs to Finalize Guidance for Coverage of Imcivree for Acquired Ho

THOMSON REUTERS
·
Aug 11

Rhythm Pharmaceuticals Announces Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity Due to Hypothalamic Injury or Impairment

THOMSON REUTERS
·
Aug 11

Rhythm Pharmaceuticals Price Target Raised to $146.00/Share from $145.00 by JP Morgan

Dow Jones
·
Aug 08

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Q2 Results And Early RM-718 Obesity Data

Simply Wall St.
·
Aug 07